JAK1 and ankylosing spondylitis: Upadacitinib is an oral JAK1 inhibitor that has been found to have significant therapeutic effects in the treatment of rheumatoid arthritis, moderate to severe atopic dermatitis, and ankylosing spondylitis (11).